X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SUN PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SUN PHARMA GLENMARK PHARMA/
SUN PHARMA
 
P/E (TTM) x 12.0 25.3 47.3% View Chart
P/BV x 3.2 3.7 85.5% View Chart
Dividend Yield % 0.4 0.6 61.5%  

Financials

 GLENMARK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
SUN PHARMA
Mar-17
GLENMARK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs993842 117.9%   
Low Rs729572 127.4%   
Sales per share (Unadj.) Rs325.5131.6 247.3%  
Earnings per share (Unadj.) Rs39.332.7 120.2%  
Cash flow per share (Unadj.) Rs48.738.0 128.1%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.20.5 46.9%  
Book value per share (Unadj.) Rs159.2152.7 104.3%  
Shares outstanding (eoy) m282.172,399.26 11.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.65.4 49.2%   
Avg P/E ratio x21.921.6 101.3%  
P/CF ratio (eoy) x17.718.6 95.0%  
Price / Book Value ratio x5.44.6 116.8%  
Dividend payout %5.110.7 47.6%   
Avg Mkt Cap Rs m242,9911,696,877 14.3%   
No. of employees `00013.017.5 74.0%   
Total wages/salary Rs m16,40849,023 33.5%   
Avg. sales/employee Rs Th7,083.918,028.3 39.3%   
Avg. wages/employee Rs Th1,265.42,798.8 45.2%   
Avg. net profit/employee Rs Th855.14,479.5 19.1%   
INCOME DATA
Net Sales Rs m91,857315,784 29.1%  
Other income Rs m3746,232 6.0%   
Total revenues Rs m92,230322,016 28.6%   
Gross profit Rs m20,367100,893 20.2%  
Depreciation Rs m2,64412,648 20.9%   
Interest Rs m2,3733,998 59.4%   
Profit before tax Rs m15,72490,479 17.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,82712,116 31.6%   
Profit after tax Rs m11,08878,462 14.1%  
Gross profit margin %22.231.9 69.4%  
Effective tax rate %24.313.4 181.8%   
Net profit margin %12.124.8 48.6%  
BALANCE SHEET DATA
Current assets Rs m68,746329,537 20.9%   
Current liabilities Rs m27,027178,870 15.1%   
Net working cap to sales %45.447.7 95.2%  
Current ratio x2.51.8 138.1%  
Inventory Days Days8579 107.6%  
Debtors Days Days9683 114.8%  
Net fixed assets Rs m24,132204,766 11.8%   
Share capital Rs m2822,399 11.8%   
"Free" reserves Rs m44,643363,997 12.3%   
Net worth Rs m44,925366,397 12.3%   
Long term debt Rs m45,36314,361 315.9%   
Total assets Rs m117,639614,102 19.2%  
Interest coverage x7.623.6 32.3%   
Debt to equity ratio x1.00 2,576.3%  
Sales to assets ratio x0.80.5 151.8%   
Return on assets %11.413.4 85.2%  
Return on equity %24.721.4 115.2%  
Return on capital %19.124.8 77.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15244,118 127.3%   
Fx outflow Rs m8,08424,484 33.0%   
Net fx Rs m48,06819,634 244.8%   
CASH FLOW
From Operations Rs m6,57470,822 9.3%  
From Investments Rs m-7,124-42,216 16.9%  
From Financial Activity Rs m5,432-22,854 -23.8%  
Net Cashflow Rs m1,9926,107 32.6%  

Share Holding

Indian Promoters % 48.3 63.7 75.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 5.1 134.5%  
FIIs % 34.4 23.0 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.3 126.5%  
Shareholders   56,727 133,026 42.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS